Search results for: NICE

Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?

1 March 2026

…and Care Excellence (NICE) or the Scottish Medicines Consortium (SMC) (OHE analysis of publicly available data)[1].  This indicates how regulatory independence, divergent evidentiary standards, and differences in HTA policies can…

Europe’s pharmaceutical policy choices – And what the United States stands to learn

18 March 2026

…misleading. For example, NICE in England approves just over four out of five medicines it appraises. But many approvals are conditional or restricted to smaller patient populations. Some medicines never enter…

The impact of inflation on incremental costs in HTA

4 June 2026

…Second, we developed a bottom-up oncology cost-effectiveness model using hypothetical interventions calibrated to three recent National Institute for Health and Care Excellence (NICE) technology appraisals (in breast cancer, non-small cell…

Masterclass: Cost-effectiveness thresholds in health technology assessment

28 April 2026, 1:00pm

…OHE experts – together with distinguished international collaborators – will guide you through: the evolution of threshold thinking, including the history behind NICE’s values how different HTA systems interpret and…

A Dose of Economics

…runs through every episode: what can health economics really bring to the most pressing problems in healthcare today?   Topics include:  NICE decision-making and cost-effectiveness thresholds  AI and its role in health…

Mid-year health check: policy, pricing & what’s coming

17 June 2026, 2:00pm

…Favored Nation (MFN) pricing and its global ripple effects to rare disease access, the recent HEMA report publication and adopting broader value perspectives in HTA, and the new NICE threshold…

Patrick Hopkinson

14 May 2026

…he served as a NICE Appeal Panel member for 10 years. Previously he worked at GSK in Global and Country roles and as a Clinical Oncology Pharmacist in the UK…

Haider Shamsi

23 June 2026

…served as a Technical Lead at the National Institute for Health and Care Excellence (NICE) in the United Kingdom, leading assessments of pharmaceuticals, medical devices, diagnostics, and innovative health technologies….

Compared to what? How the choice of comparator affects new medicines

14 September 2026

…for. Some HTA agencies, such as NICE, may accept an ‘off-label’ medicine, in which case, the comparator’s cost can vary considerably depending on its exclusivity status, producing effects on access…